New AI tool helps some breast cancer patients with early-stage disease assess recurrence risk

A new artificial intelligence-powered tool aims to use some breast cancer patients’ MRI, pathology, and clinical data to define their risk of recurrence to come up with more precise treatments.SimBioSys, a Chicago-based software company born in a lab at the University of Illinois, created TumorSight Risk as a prognostic tool for cancer centers treating patients with early-stage, hormone receptor-positive breast cancer.Stacey Stevens, the president and chief executive officer of SimBioSys, recently celebrated the U.S. Food and Drug Administration’s clearance of TumorSight Risk to be used as a prognostic indicator of recurrence-free survival at five and ten years in some patients. The tool is designed for women who have been diagnosed with breast cancer that has three characteristics: It is hormone receptor-positive, which means that the cancer cells have receptors that attach to estrogen or progesterone. It is HER2-negative, which means the cancer cells don’t have high levels of the hum